摘要
目的探讨三磷酸腺苷生物荧光法（ATP—TCA）体外药敏试验在复发或难治非霍奇金淋巴瘤（NHL）治疗中的临床应用价值。方法应用ATP—TCA技术对复发或耐药淋巴瘤患者术后新鲜组织标本共34例进行体外药敏试验，观察用敏感药物化疗疗效。结果淋巴瘤标本的药物敏感性具有个体差异性，不同化疗药物的体外抑瘤活性不同。药敏试验组总有效率（RR）为82．4％（28／34），完全缓解（CR）率为52．9％（18／34）；DICE化疗组RR为60．0％（18／30），CR率为33．3％（10／30）；GDP化疗组RR为62．3％（33／53），CR率为26．4％（14／53）。药敏试验组的RR与DICE组及GDP组相比，差异有统计学意义（x2=3．93，P=0．047；x2=3．98，P=0．046）。结论ATP—TCA体外药敏检测结果与临床治疗反应有很好的相关性，是开展肿瘤个体化化疗的一种重要的体外药物筛选方法。
Objective To investigate the clinical value of ATP bioluminescence tumor chemosensitivity assay （ATP-TCA） for recurrent and refractory non-Hodgkin lymphoma （NHL） specimens in vitro. Methods Thirty-four freshly taken recurrent and refractory NHL specimens were tested in vitro for cancer chemosensitivity by ATP-TCA. Results Drug sensitivity of NHL specimens had heterogeneity. Different drugs had different tumor growth inhibition ratio in vitro. Response rate （RR） of the patients receiving chemotherapy according to in vitro assay was 82.4 % （28/34）, complete response rate （CR） was 52.9 % （18/34）. In DICE group RR was 60.0 % （18/30）, CR rate was 33.3 % （10/30）. In GDP group RR was 62.3 % （33/53）, CR rate was 26.4 % （14/53）. In ATP-TCA group RR was significantly higher than those in DICE and GDP groups （X2 = 3.93, P = 0.047; X2 =3.98, P = 0.046）. Conclusion The results of ATP-TCA assay are correlated well with clinical treatment responses. The assay may be an important and useful method for individual-based chemotherapy of cancers.
出处
《白血病．淋巴瘤》
CAS
2011年第10期590-593,共4页
Journal of Leukemia & Lymphoma
基金
基金项目：南通市科技局指令性课题随卫规财2006（29号）]
